{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T04:40:07Z","timestamp":1759466407231,"version":"build-2065373602"},"reference-count":53,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"C2N Diagnostics, LLC"},{"name":"Gerald and Henrietta Rauenhorst Foundation (GHR), Alzheimer\u2019s Drug Discovery Foundation","award":["GC-201711-2013978"],"award-info":[{"award-number":["GC-201711-2013978"]}]},{"DOI":"10.13039\/100006312","name":"BrightFocus","doi-asserted-by":"crossref","award":["CA2016636"],"award-info":[{"award-number":["CA2016636"]}],"id":[{"id":"10.13039\/100006312","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["R44 AG059489"],"award-info":[{"award-number":["R44 AG059489"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.mdpi.com"],"crossmark-restriction":true},"short-container-title":["JPM"],"abstract":"<jats:p>Background\/Objectives: A high-performing blood biomarker (BBM) test for Alzheimer\u2019s disease (AD) represents an accurate, accessible, and scalable tool to aid healthcare professionals (HCPs) evaluating patients presenting with signs or symptoms of mild cognitive impairment (MCI) or dementia. However, implementation of AD blood tests into clinical practice has not been extensively evaluated. The objective of this study was to assess the implementation of the multi-analyte PrecivityAD2\u2122 blood test (C2N Diagnostics, LLC, St. Louis, MO, USA) into the clinical workflow of memory care clinics. Methods: A total of 8 HCPs (neurologists, geriatricians, geriatric psychiatrists) who served as site directors from 8 outpatient sites that evaluated 203 cognitively symptomatic patients were included in this sub-study of the real-world QUIP II Study (NCT06025877). Implementation of this blood test was assessed through surveying these HCPs using published frameworks including the Technology Acceptance Model, net promoter score, and forced choice preference questions. These assessments were analyzed using Wilcoxon signed-rank test, Fisher\u2019s Exact test, and Wilcoxon signed-rank test, respectively. Results: HCPs reported acceptance scores that averaged 9.6 out of 10 (p &lt; 0.0001, effect size 0.840): the test\u2019s contribution to clinical decision-making as well as the ease of understanding test results received the highest ratings. The net promoter score was 75 (p &lt; 0.0001), exceeding the typical benchmark of 30 reported as good levels of satisfaction in healthcare settings. The APS2 results and individual blood analyte results were rated with similar preference around their roles in HCP clinical decision-making. Conclusions: The results indicate early evidence of user acceptance and recognition by HCPs that this AD blood test can personalize the clinical care pathway for evaluating cognitively symptomatic patients.<\/jats:p>","DOI":"10.3390\/jpm15100469","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:27:42Z","timestamp":1759328862000},"page":"469","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Implementation of an Alzheimer\u2019s Disease Blood Test: Adoption Experience by Memory Care Specialists in a Multi-Center Study"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1550-4415","authenticated-orcid":false,"given":"Mark","family":"Monane","sequence":"first","affiliation":[{"name":"C2N Diagnostics, LLC, 4340 Duncan Avenue, St. Louis, MO 63110, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7263-3309","authenticated-orcid":false,"given":"Robert M.","family":"Carlile","sequence":"additional","affiliation":[{"name":"Palmetto Primary Care Physicians, Summerville, SC 29486, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8793-2489","authenticated-orcid":false,"given":"Kim G.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Department of Neurology, Duke University School of Medicine, Durham, NC 27710, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6057-5605","authenticated-orcid":false,"given":"Darren R.","family":"Gitelman","sequence":"additional","affiliation":[{"name":"Advocate Memory Center and the Advocate Aurora Research Institute, Advocate Aurora Health, Downers Grove, IL 60015, USA"},{"name":"Advocate Lutheran General Hospital, Park Ridge, IL 60068, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawren A.","family":"VandeVrede","sequence":"additional","affiliation":[{"name":"Memory and Aging Center, Weill Institute for Neurology, Department of Neurology, University of California, San Francisco, CA 94158, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Demetrius M.","family":"Maraganore","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tulane University School of Medicine, New Orleans, LA 70112, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Merrill","sequence":"additional","affiliation":[{"name":"Pacific Neuroscience Institute, Santa Monica, CA 90404, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leslie","family":"Jacobs","sequence":"additional","affiliation":[{"name":"C2N Diagnostics, LLC, 4340 Duncan Avenue, St. Louis, MO 63110, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4137-930X","authenticated-orcid":false,"given":"Justine","family":"Coppinger","sequence":"additional","affiliation":[{"name":"C2N Diagnostics, LLC, 4340 Duncan Avenue, St. Louis, MO 63110, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip B.","family":"Verghese","sequence":"additional","affiliation":[{"name":"C2N Diagnostics, LLC, 4340 Duncan Avenue, St. Louis, MO 63110, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3267-8249","authenticated-orcid":false,"given":"Tim","family":"West","sequence":"additional","affiliation":[{"name":"C2N Diagnostics, LLC, 4340 Duncan Avenue, St. Louis, MO 63110, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel B.","family":"Braunstein","sequence":"additional","affiliation":[{"name":"C2N Diagnostics, LLC, 4340 Duncan Avenue, St. Louis, MO 63110, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Drugan, T., and Leucu\u021ba, D. (2024). Evaluating Novel Biomarkers for Personalized Medicine. Diagnostics, 14.","DOI":"10.3390\/diagnostics14060587"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1001\/jama.2024.13855","article-title":"Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care","volume":"332","author":"Palmqvist","year":"2024","journal-title":"JAMA"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s13195-023-01272-z","article-title":"Expected and diagnosed rates of mild cognitive impairment and dementia in the U.S. Medicare population: Observational analysis","volume":"15","author":"Mattke","year":"2023","journal-title":"Alzheimers Res. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e14338","DOI":"10.1002\/alz.14338","article-title":"Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer\u2019s Association and Society for Nuclear Medicine and Molecular Imaging Workgroup","volume":"21","author":"Rabinovici","year":"2025","journal-title":"Alzheimers Dement."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1212\/WNL.0000000000001991","article-title":"Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease","volume":"85","author":"Palmqvist","year":"2015","journal-title":"Neurology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.jacr.2012.05.005","article-title":"Geographic and sociodemographic disparities in PET use by Medicare beneficiaries with cancer","volume":"9","author":"Onega","year":"2012","journal-title":"J. Am. Coll. Radiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/alz.12372","article-title":"State-of-the-art of lumbar puncture and its place in the journey of patients with Alzheimer\u2019s disease","volume":"18","author":"Hampel","year":"2022","journal-title":"Alzheimers Dement."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"8209","DOI":"10.1002\/alz.14150","article-title":"Considerations for widespread implementation of blood-based biomarkers of Alzheimer\u2019s disease","volume":"20","author":"Mielke","year":"2024","journal-title":"Alzheimers Dement."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1002\/alz.12756","article-title":"The Alzheimer\u2019s Association appropriate use recommendations for blood biomarkers in Alzheimer\u2019s disease","volume":"18","author":"Hansson","year":"2022","journal-title":"Alzheimers Dement."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"8216","DOI":"10.1002\/alz.14184","article-title":"Recommendations for clinical implementation of blood-based biomarkers for Alzheimer\u2019s disease","volume":"20","author":"Mielke","year":"2024","journal-title":"Alzheimers Dement."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/s41582-024-00977-5","article-title":"Acceptable performance of blood biomarker tests of amyloid pathology\u2014Recommendations from the Global CEO Initiative on Alzheimer\u2019s Disease","volume":"20","author":"Schindler","year":"2024","journal-title":"Nat. Rev. Neurol."},{"key":"ref_12","first-page":"e70069","article-title":"Understanding the impact of amyloid beta targeted therapies on biomarkers and clinical endpoints in Alzheimer\u2019s disease","volume":"11","author":"Petersen","year":"2025","journal-title":"Alzheimers Dement."},{"key":"ref_13","first-page":"123","article-title":"Alzheimer\u2019s Disease\u2014Why We Need Early Diagnosis","volume":"9","author":"Rasmussen","year":"2019","journal-title":"Degener. Neurol. Neuromuscul. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1002\/alz.13764","article-title":"Clinical validation of the PrecivityAD2 blood test: A mass spectrometry-based test with algorithm combining %p-tau217 and A\u03b242\/40 ratio to identify presence of brain amyloid","volume":"20","author":"Meyer","year":"2024","journal-title":"Alzheimer Dement."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s44400-025-00026-y","article-title":"Independent validation of the PrecivityAD2\u2122 blood test to identify presence or absence of brain amyloid pathology in individuals with cognitive impairment","volume":"1","author":"Coppinger","year":"2025","journal-title":"NPJ Dement."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1007\/s00415-025-12996-3","article-title":"Blood phosphorylated Tau217 distinguishes amyloid-positive from amyloid-negative subjects in the Alzheimer\u2019s disease continuum. A systematic review and meta-analysis","volume":"272","author":"Antonioni","year":"2025","journal-title":"J. Neurol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S1474-4422(16)00070-3","article-title":"CSF and blood biomarkers for the diagnosis of Alzheimer\u2019s disease: A systematic review and meta-analysis","volume":"15","author":"Olsson","year":"2016","journal-title":"Lancet Neurol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Monane, M., Maraganore, D.M., Carlile, R.M., Johnson, K.G., Merrill, D.A., Gitelman, D.R., Sharlin, K.S., VandeVrede, L.A., George, K.K., and Wang, J. (2025). Clinical Utility of an Alzheimer\u2019s Disease Blood Test Among Cognitively Impaired Patients: Results from the Quality Improvement PrecivityAD2 (QUIP II) Clinician Survey Study. Diagnostics, 15.","DOI":"10.3390\/diagnostics15020167"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2307\/249008","article-title":"Perceived usefulness, perceived ease of use, and user acceptance of information technology","volume":"13","author":"Davis","year":"1989","journal-title":"MIS Q."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Eastwood, S.M., Meyer, M.R., Kirmess, K.M., Wente-Roth, T.L., Irvin, F., Holubasch, M.S., Verghese, P.B., West, T., Braunstein, J.B., and Yarasheski, K.E. (2024). PrecivityAD2\u2122 Blood Test: Analytical Validation of an LC-MS\/MS Assay for Quantifying Plasma Phospho-tau217 and Non-Phospho-tau217 Peptide Concentrations That Are Used with Plasma Amyloid-\u03b242\/40 in a Multianalyte Assay with Algorithmic Analysis for Detecting Brain Amyloid Pathology. Diagnostics, 14.","DOI":"10.20944\/preprints202406.1343.v1"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.cca.2021.05.011","article-title":"The PrecivityAD\u2122 test: Accurate and reliable LC-MS\/MS assays for quantifying plasma amyloid beta 40 and 42 and apolipoprotein E proteotype for the assessment of brain amyloidosis","volume":"519","author":"Kirmess","year":"2021","journal-title":"Clin. Chim. Acta"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Muller-Gass, A., Mukerjee, G., Dorfman, R., and Jetly, R. (2025). Implementation of Pharmacogenomics Testing in Daily Clinical Practice: Perspectives of Prescribers from Two Canadian Armed Forces Medical Clinics. J. Pers. Med., 15.","DOI":"10.3390\/jpm15030101"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Nguyen, M., Fujioka, J., Wentlandt, K., Onabajo, N., Wong, I., Bhatia, R.S., Bhattacharyya, O., and Stamenova, V. (2020). Using the technology acceptance model to explore health provider and administrator perceptions of the usefulness and ease of using technology in palliative care. BMC Palliat. Care, 19.","DOI":"10.1186\/s12904-020-00644-8"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1055\/s-0038-1668091","article-title":"A Systematic Review of the Technology Acceptance Model in Health Informatics","volume":"9","author":"Rahimi","year":"2018","journal-title":"Appl. Clin. Inf."},{"key":"ref_25","first-page":"46","article-title":"The One Number You Need to Grow","volume":"81","author":"Reichheld","year":"2003","journal-title":"Harv. Bus. Rev."},{"key":"ref_26","unstructured":"(2025, September 02). What is NPS?. Qualtrics., Available online: https:\/\/www.qualtrics.com\/experience-management\/customer\/net-promoter-score\/."},{"key":"ref_27","unstructured":"SurveyMonkey (2025, September 05). What is NPS in Healthcare?. 2025., Available online: https:\/\/www.surveymonkey.com\/mp\/healthcare-nps\/."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"(2025, September 07). OECDi Library. Available online: https:\/\/doi.org\/10.1787\/9789264167179-en.","DOI":"10.1787\/9789264167179-en"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1111\/hex.12098","article-title":"Choosing vs. allocating: Discrete choice experiments and constant-sum paired comparisons for the elicitation of societal preferences","volume":"18","author":"Skedgel","year":"2015","journal-title":"Health Expect."},{"key":"ref_30","unstructured":"(2025, September 05). SurveyMonkey. What Is a Likert Scale? Definition, Examples, and Tips. Available online: https:\/\/www.surveymonkey.com\/mp\/likert-scale\/."},{"key":"ref_31","first-page":"671","article-title":"Analysis of paired Likert data: How to evaluate change and preference questions","volume":"27","author":"Roberson","year":"1995","journal-title":"Fam. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.3949\/ccjm.84.s2.04","article-title":"Chi-square and Fisher\u2019s exact tests (From the \u201cBiostatistics and Epidemiology Lecture Series, Part 1\u201d)","volume":"84","author":"Nowacki","year":"2017","journal-title":"Cleve. Clin. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1152\/advan.00017.2010","article-title":"When t-tests or Wilcoxon-Mann-Whitney tests won\u2019t do","volume":"34","author":"McElduff","year":"2010","journal-title":"Adv. Physiol. Educ."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"igz036","DOI":"10.1093\/geroni\/igz036","article-title":"Effect Size Guidelines, Sample Size Calculations, and Statistical Power in Gerontology","volume":"3","author":"Brydges","year":"2019","journal-title":"Innov. Aging"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13012-019-0897-z","article-title":"Designing high-quality implementation research: Development, application, feasibility and preliminary evaluation of the implementation science research development (ImpRes) tool and guide","volume":"14","author":"Hull","year":"2019","journal-title":"Implement. Sci."},{"key":"ref_36","first-page":"182","article-title":"Implementation Research: An Efficient and Effective Tool to Accelerate Universal Health Coverage","volume":"9","author":"Binagwaho","year":"2020","journal-title":"Int. J. Health Policy Manag."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1478-7547-10-9","article-title":"From efficacy to equity: Literature review of decision criteria for resource allocation and healthcare decisionmaking","volume":"10","author":"Guindo","year":"2012","journal-title":"Cost. Eff. Resour. Alloc."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"112376","DOI":"10.1016\/j.psychres.2019.04.025","article-title":"Implementation science: What is it and why should I care?","volume":"283","author":"Bauer","year":"2020","journal-title":"Psychiatry Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e126","DOI":"10.1017\/cts.2021.789","article-title":"Understanding and applying the RE-AIM framework: Clarifications and resources","volume":"5","author":"Holtrop","year":"2021","journal-title":"J. Clin. Transl. Sci."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Jones, L.K., Strande, N.T., Calvo, E.M., Chen, J., Rodriguez, G., McCormick, C.Z., Hallquist, M.L.G., Savatt, J.M., Rocha, H., and Williams, M.S. (2022). A RE-AIM Framework Analysis of DNA-Based Population Screening: Using Implementation Science to Translate Research Into Practice in a Healthcare System. Front. Genet., 13.","DOI":"10.3389\/fgene.2022.883073"},{"key":"ref_41","unstructured":"Drive Research (2025, July 08). What is a Healthcare Net Promoter Score?. Available online: https:\/\/www.driveresearch.com\/market-research-company-blog\/healthcare-net-promoter-score-definition-formula-benchmarks\/."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e13197","DOI":"10.1111\/ijn.13197","article-title":"From Detractors to Promoters: A comparative analysis of patient experience drivers across Net Promoter Score subcategories","volume":"30","author":"Adams","year":"2024","journal-title":"Int. J. Nurs. Pract."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e2460637","DOI":"10.1001\/jamanetworkopen.2024.60637","article-title":"Clinician Experiences With Ambient Scribe Technology to Assist With Documentation Burden and Efficiency","volume":"8","author":"Duggan","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2152941","DOI":"10.1080\/21614083.2022.2152941","article-title":"Net Promoter Score (NPS): What Does Net Promoter Score Offer in the Evaluation of Continuing Medical Education?","volume":"11","author":"Lucero","year":"2022","journal-title":"J. Eur. CME"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ejor.2007.05.001","article-title":"The analytic hierarchy process in medical and health care decision making: A literature review","volume":"189","author":"Liberatore","year":"2008","journal-title":"Eur. J. Oper. Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s40271-014-0077-9","article-title":"Constant-sum paired comparisons for eliciting stated preferences: A tutorial","volume":"8","author":"Skedgel","year":"2015","journal-title":"Patient"},{"key":"ref_47","unstructured":"Albrecht, C. (2025, September 04). Constant Sum Allocation Deserves a Closer Look. TRC. Available online: https:\/\/trcmarketresearch.com\/blog\/constant-sum-allocation-deserves-a-closer-look\/."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1111\/hex.13577","article-title":"The ultimate question? Evaluating the use of Net Promoter Score in healthcare: A systematic review","volume":"25","author":"Adams","year":"2022","journal-title":"Health Expect."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e2321","DOI":"10.1002\/bdm.2321","article-title":"The common origin of both oversimplified and overly complex decision rules","volume":"36","author":"Bonder","year":"2023","journal-title":"J. Behav. Decis. Mak."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1017\/S0266462322000927","article-title":"OP35 Suitability Of Preference Methods Across The Medical Product Lifecycle: A Multicriteria Decision Analysis","volume":"38","author":"Veldwijk","year":"2022","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1089\/pop.2023.0309","article-title":"Use of a Blood Biomarker Test Improves Economic Utility in the Evaluation of Older Patients Presenting with Cognitive Impairment","volume":"27","author":"Canestaro","year":"2024","journal-title":"Popul. Health Manag."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"100219","DOI":"10.1016\/j.tjpad.2025.100219","article-title":"Estimation of the value-based price of a blood test for Alzheimer\u2019s disease pathology in primary and specialty care in the U.S","volume":"12","author":"Mattke","year":"2025","journal-title":"J. Prev. Alzheimers Dis."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Canestaro, W.J., Monane, M., Bateman, R.J., Holtzman, D.M., and Braunstein, J.B. (2025, January 27\u201331). The Economic Utility of an Alzheimer\u2019s Disease Blood Biomarker Test in the Evaluation of Cognitively Impaired Patients. Proceedings of the Alzheimer\u2019s Association International Conference, Toronto, ON, Canada.","DOI":"10.1089\/pop.2023.0309"}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/15\/10\/469\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T04:23:58Z","timestamp":1759465438000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/15\/10\/469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"references-count":53,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["jpm15100469"],"URL":"https:\/\/doi.org\/10.3390\/jpm15100469","relation":{},"ISSN":["2075-4426"],"issn-type":[{"type":"electronic","value":"2075-4426"}],"subject":[],"published":{"date-parts":[[2025,10,1]]}}}